Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 12/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949949 | 1.00 | F9 (0.48) | F9ROCK2ROCK1KDM1AMAOA | |
| SCHEMBL7902251 | 0.85 | F9 (0.67) | F9KDM1AMAOAMAOBKDM1B | |
| SCHEMBL1949444 | 0.85 | F9 (0.67) | F9KDM1AMAOAMAOBKDM1B | |
| SCHEMBL1949449 | 0.84 | F9 (0.49) | F9ROCK2ROCK1KDM1AMAOA | |
| Ammonia Solution, Strong SCHEMBL1949006 | 0.79 | F9 (0.46) | F9 | |
| SCHEMBL7902685 | 0.76 | F9 (0.52) | F9 | |
| SCHEMBL12569559 | 0.76 | F9 (0.42) | F9ROCK2ROCK1KDM1AMAOA | |
| SCHEMBL17244574 | 0.75 | F9 (0.41) | F9 | |
| SCHEMBL12547036 | 0.73 | F9 (0.38) | F9ROCK2 | |
| Hydrochloric Acid SCHEMBL1948787 | 0.73 | F9 (0.54) | F9KDM1AMAOAMAOBKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885ROCK2 1687/4885ROCK1 847/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885ROCK2 1687/4885ROCK1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.